Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of empagliflozin vs glimepiride in type 2 diabetes inadequately controlled on metformin
2009-016244-39Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in HbA1c at 52 weeks and Change in HbA1c at 104 weeks. Started Apr 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016244-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016244-39.